AI Algorithms Need FDA-Style Drug Trials

#artificialintelligence 

Imagine a couple of caffeine-addled biochemistry majors late at night in their dorm kitchen cooking up a new medicine that proves remarkably effective at soothing colds but inadvertently causes permanent behavioral changes. Those who ingest it become radically politicized and shout uncontrollably in casual conversation. Still, the concoction sells to billions of people. This sounds preposterous, because the FDA would never let such a drug reach the market. Olaf J. Groth is founding CEO of Cambrian Labs and a professor at Hult Business School.